Renaissance Technologies (RenTech)'s ESPR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 160,200 shares of Esperion Therapeutics, Inc. (ESPR) worth $506,232, representing 0.00% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ESPR, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 1.42 M shares. Largest reduction occurred in Q2 2026, reducing 1.46 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Esperion Therapeutics (ESPR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Esperion Therapeutics (ESPR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -1.46 M | Reduce 90.11% | 160,200 | $3.16 |
| Q1 2026 | -574,500 | Reduce 26.18% | 1.62 M | $2.74 |
| Q4 2025 | +1.42 M | Add 183.58% | 2.19 M | $3.70 |
| Q3 2025 | +481,500 | Add 164.67% | 773,900 | $2.65 |
| Q2 2025 | +292,400 | New Buy | 292,400 | $0.98 |
| Q1 2025 | -578,800 | Sold Out | 0 | $0.00 |
| Q4 2024 | -335,300 | Reduce 36.68% | 578,800 | $2.20 |
| Q3 2024 | -507,800 | Reduce 35.71% | 914,100 | $1.65 |
| Q2 2024 | -694,600 | Reduce 32.82% | 1.42 M | $2.22 |
| Q1 2024 | +696,400 | Add 49.04% | 2.12 M | $2.68 |
| Q4 2023 | +1.21 M | Add 588.85% | 1.42 M | $2.99 |
| Q3 2023 | +91,856 | Add 80.36% | 206,156 | $0.98 |
| Q2 2023 | +114,300 | New Buy | 114,300 | $0.00 |
| Q4 2022 | -286,700 | Sold Out | 0 | $0.00 |
| Q3 2022 | -98,600 | Reduce 25.59% | 286,700 | $6.70 |
| Q2 2022 | -36,900 | Reduce 8.74% | 385,300 | $6.36 |
| Q1 2022 | +422,200 | New Buy | 422,200 | $4.64 |
| Q4 2019 | -141,900 | Sold Out | 0 | $0.00 |
| Q3 2019 | -95,600 | Reduce 40.25% | 141,900 | $36.66 |
| Q2 2019 | +41,905 | Add 21.42% | 237,500 | $46.52 |
| Q1 2019 | +177,695 | Add 992.71% | 195,595 | $40.15 |
| Q4 2018 | +17,900 | New Buy | 17,900 | $45.98 |
| Q4 2017 | -14,500 | Sold Out | 0 | $0.00 |
| Q3 2017 | +14,500 | New Buy | 14,500 | $50.14 |
| Q4 2016 | -318,800 | Sold Out | 0 | $0.00 |
| Q3 2016 | +318,800 | New Buy | 318,800 | $13.85 |
| Q2 2016 | -107,600 | Sold Out | 0 | $0.00 |
| Q1 2016 | -253,600 | Reduce 70.21% | 107,600 | $16.91 |
| Q4 2015 | +361,200 | New Buy | 361,200 | $22.26 |
Renaissance Technologies (RenTech)'s Esperion Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Esperion Therapeutics, Inc. (ESPR) in Q4 2015, acquiring 361,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Esperion Therapeutics, Inc. (ESPR) for 29 quarters since Q4 2015.
Renaissance Technologies (RenTech)'s largest addition to Esperion Therapeutics, Inc. (ESPR) was in Q4 2025, adding 2,194,600 shares worth $8.12 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 160,200 shares of Esperion Therapeutics, Inc. (ESPR), valued at approximately $506,232.
As of the Q2 2026 filing, Esperion Therapeutics, Inc. (ESPR) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Esperion Therapeutics, Inc. (ESPR) was 2,194,600 shares, as reported at the end of Q4 2025.